Eisai Co., Ltd. (“Eisai”) put out today the following press release about E6011, which Eisai has developed jointly with its gastrointestinal area subsidiary EA Pharma Co., Ltd.
|
EISAI PRESENTS LATEST PHASE I/II DATA ON
IN-HOUSE DEVELOPED ANTI-FRACTALKINE
ANTIBODY E6011
RESULTS SUGGEST SAFETY, TOLERABILITY AS
WELL AS CLINICAL ACTIVITY
IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE
|
For full text of the press release, please see the URL below in the website of Eisai Co., Ltd.
http://www.eisai.com/news/news201640.html
EA pharma Co., Ltd.
Corporate Planning Dept.
